University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer

Simple item page
dc.contributor.authorVolpato, Milene
dc.contributor.authorCummings, Michele
dc.contributor.authorShaaban, Abeer M
dc.contributor.authorAbderrahman, Balkees
dc.contributor.authorHull, Mark A
dc.contributor.authorMaximov, Philipp Y.
dc.contributor.authorBroom, Bradley M.
dc.contributor.authorHoppe, Reiner
dc.contributor.authorFan, Ping
dc.contributor.authorBrauch, Hiltrud
dc.contributor.authorJordan, V Craig
dc.contributor.authorSpeirs, Valerie
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.date.accessioned2021-03-23T20:21:01Z
dc.date.available2021-03-23T20:21:01Z
dc.date.issued2020-10-30
dc.descriptionAcknowledgments We thank Werbena Hamilton-Burke, Loaie Maraqa and Mark Peter for providing clinical data on the breast tumours which populated the TMAs used in this study. Funding: This work was supported in part by Cancer Research UK grant C13432/A9047; Yorkshire Cancer Research grant L314; the Robert Bosch Foundation, Stuttgart, Germany; the NIH; MD Anderson’s Cancer Center support grant CA016672; the George and Barbara Bush Foundation for Innovative Cancer Research; and the Dallas/Fort Worth Living Legend Chair of Cancer Research. The study sponsor(s) played no part in the study design; in the collection, analysis and interpretation of the data; in the writing of the report; and in the decision to submit the paper for publication.en
dc.description.statusPeer revieweden
dc.format.extent17
dc.format.extent4861841
dc.identifier178239322
dc.identifierfcba0d40-4b7d-4bc7-963b-d7f01fd940bc
dc.identifier33210098
dc.identifier85120404785
dc.identifier.citationVolpato, M, Cummings, M, Shaaban, A M, Abderrahman, B, Hull, M A, Maximov, P Y, Broom, B M, Hoppe, R, Fan, P, Brauch, H, Jordan, V C & Speirs, V 2020, 'Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer', Exploration of Targeted Anti-tumor Therapy, vol. 1, pp. 355-371. https://doi.org/10.37349/etat.2020.00021en
dc.identifier.doi10.37349/etat.2020.00021
dc.identifier.issn2692-3114
dc.identifier.otherORCID: /0000-0002-0602-4666/work/82658896
dc.identifier.urihttps://hdl.handle.net/2164/16111
dc.identifier.vol1en
dc.language.isoeng
dc.relation.ispartofExploration of Targeted Anti-tumor Therapyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectBreast canceren
dc.subjectendocrine resistanceen
dc.subject15-hydroxyprostaglandin dehydrogenaseen
dc.subjectimmunohistochemistryen
dc.subjectsurvivalen
dc.subjectR Medicineen
dc.subjectCancer Research UKen
dc.subjectC13432/A9047en
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleDownregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast canceren
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Volpato_etal_Downregulation_of_15_hydroxyprostaglandin_VOR.pdf
Size:
4.64 MB
Format:
Adobe Portable Document Format
Download

Collections

All research